LeMaitre Vascular (NASDAQ:LMAT) Announces Quarterly Earnings Results

LeMaitre Vascular (NASDAQ:LMAT) issued its quarterly earnings results on Thursday. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05, Briefing.com reports. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same quarter in the prior year, the business posted $0.33 EPS. LeMaitre Vascular’s revenue for the quarter was up 15.6% compared to the same quarter last year.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $94.88 on Friday. The stock has a market capitalization of $2.13 billion, a PE ratio of 56.81, a P/E/G ratio of 2.33 and a beta of 0.88. LeMaitre Vascular has a fifty-two week low of $45.96 and a fifty-two week high of $101.67. The company has a fifty day moving average of $89.59 and a two-hundred day moving average of $82.98.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be paid a $0.16 dividend. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.67%. LeMaitre Vascular’s dividend payout ratio is currently 38.32%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Lake Street Capital initiated coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price on the stock. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Barrington Research upped their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday. JMP Securities upped their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a report on Friday. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $94.57.

Insider Activity

In related news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at $1,158,335.98. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.